AlzeCure Pharma — Investor Relations & Filings

AlzeCure Pharma is a pharmaceutical company engaged in the research and development of therapies for severe diseases, with a primary focus on Alzheimer's disease and a secondary focus on pain. The company develops a broad portfolio of symptomatic, disease-modifying, and preventive drug candidates. Its research is centered on two key platforms: NeuroRestore, which focuses on symptomatic treatments, and Alzstatin, which develops disease-modifying and preventive candidates for early-stage Alzheimer's. A lead candidate from the NeuroRestore platform, ACD856, is advancing to Phase II clinical trials for Alzheimer's disease. The company's strategy is to address high unmet medical needs in central nervous system (CNS) disorders.